MINOS1 Activators
MINOS1 Activators comprise a spectrum of chemical compounds that indirectly enhance the functional activity of MINOS1 by targeting several signaling pathways and cellular processes integral to mitochondrial dynamics. Forskolin and Sildenafil exert their effects by increasing cAMP and cGMP levels, respectively, which activate PKA and could lead to phosphorylation of proteins within the MINOS1 pathway, thus enhancing MINOS1's role in mitochondrial morphology regulation. Similarly, Resveratrol and SRT1720, through SIRT1 activation, facilitate deacetylation of mitochondrial proteins, potentially improving mitochondrial fusion and health, activities where MINOS1 has vital importance. Pioglitazone and Bezafibrate act as PPAR-gamma and PPAR isoform agonists, respectively, which are known to promote mitochondrial biogenesis-a process that would logically require robust MINOS1 activity### Question 2: MINOS1 Activators
MINOS1 Activators consist of a diverse array of chemical compounds that indirectly augment the functional activity of MINOS1 through distinct yet interconnected signaling pathways and cellular processes pivotal to mitochondrial integrity and dynamics. Compounds like Forskolin and Sildenafil elevate intracellular levels of cAMP and cGMP, respectively, leading to the activation of PKA, which may phosphorylate proteins within the MINOS1-associated pathways, thereby facilitating MINOS1's involvement in the maintenance of mitochondrial morphology. Resveratrol and SRT1720, by stimulating SIRT1, bring about the deacetylation of mitochondrial proteins, potentially enhancing mitochondrial fusion and function-processes in which MINOS1 plays a critical role. Pioglitazone and Bezafibrate, as agonists of PPAR-gamma and PPAR isoforms, are implicated in the enhancement of mitochondrial biogenesis, which necessitates the active participation of MINOS1 to ensure proper mitochondrial network formation and maintenance.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate various targets, potentially leading to enhanced MINOS1 activity involved in mitochondrial fusion. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid modulates gene expression through retinoid receptors. By influencing nuclear receptor signaling, it could enhance the expression of proteins like MINOS1 that are involved in mitochondrial biogenesis and dynamics. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
An inhibitor of DNA methyltransferases, 5-Azacytidine, can lead to the demethylation of genes and consequent upregulation of proteins. This may increase the levels of MINOS1 if its gene expression is epigenetically regulated. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By altering the chromatin structure, it can increase the transcription of certain genes, which may include those coding for proteins like MINOS1 involved in chromatin remodeling. | ||||||
SRT1720 | 1001645-58-4 | sc-364624 sc-364624A | 5 mg 10 mg | $197.00 $364.00 | 13 | |
SRT1720 is a SIRT1 activator. SIRT1 activation can lead to deacetylation of proteins involved in mitochondrial function, which could enhance the activity of mitochondrial proteins like MINOS1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
As a SIRT1 activator, Resveratrol can promote deacetylation of mitochondrial proteins, potentially leading to the activation of MINOS1 function in mitochondrial fusion and biogenesis. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a PPARγ agonist, can modulate transcription of genes related to mitochondrial function and biogenesis. This pharmacological action could indirectly enhance MINOS1 activity. | ||||||
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $31.00 $46.00 $122.00 $204.00 | 5 | |
Bezafibrate acts as a PPAR pan-agonist and can induce the expression of genes involved in mitochondrial function, potentially leading to an increase in MINOS1 activity within the mitochondrial matrix. | ||||||
Mdivi-1 | 338967-87-6 | sc-215291 sc-215291B sc-215291A sc-215291C | 5 mg 10 mg 25 mg 50 mg | $67.00 $126.00 $251.00 $465.00 | 13 | |
Mdivi-1 is a selective inhibitor of mitochondrial division. Its use can lead to increased mitochondrial fusion, a process in which MINOS1 is involved, thus indirectly enhancing MINOS1 activity. | ||||||
Nicotinamide riboside | 1341-23-7 | sc-507345 | 10 mg | $411.00 | ||
Nicotinamide Riboside enhances NAD+ levels, which can upregulate SIRT1 activity. This activation may influence mitochondrial dynamics and function, potentially increasing MINOS1 activity related to mitochondrial health. | ||||||